Publication:
Effect of methylglyoxal on Parkinson’s disease pathophysiology in the rotenone model

Simple item page
dc.contributor.authorYILMAZ, BETÜL
dc.contributor.authorGÜLHAN, REZZAN
dc.contributor.authorsCulpan Y., Ozden L., Gozderesi Y., Kocak B., Baltaci Z. H., Denizli A., Karademir Yilmaz B., GÜLHAN R.
dc.date.accessioned2024-08-08T12:40:19Z
dc.date.available2024-08-08T12:40:19Z
dc.date.issued2024-05-31
dc.description.abstractObjective: Type 2 diabetes mellitus patients have been reported to have a higher incidence of Parkinson’s disease. This study aimed to explore the effect of advanced glycation end products precursor methylglyoxal (MGO) on the pathophysiology of Parkinson’s disease in a rotenone model. Materials and Methods: Adult female Wistar rats (n=42) were divided into four groups. Rotenone toxicity was assessed by daily weight measurements and mortality rates. Effect of MGO on blood glucose was evaluated. Locomotor activity, rearing, and rotarod tests were performed to evaluate motor functions, and for neurodegeneration, tyrosine hydroxylase immunoreactivity in the striatum and substantia nigra regions was assessed. Results: The mortality rate was 9% in the rotenone-applied rats. The mean weight, locomotor activity, rearing activity, and longest time spent on a rotarod were lower in the MGO+Rotenone group than in the Control group. Tyrosine hydroxylase immunoreactivity in the striatum rostral to the anterior commissure in the MGO+Rotenone group was lower than that in the Control and MGO groups. The number of tyrosine hydroxylase positive cells in the substantia nigra pars compacta was comparable among the groups. Conclusion: When nigrostriatal degeneration was triggered, MGO was found to worsen motor dysfunction and increase damage to dopaminergic neuron projections.
dc.identifier.citationCulpan Y., Ozden L., Gozderesi Y., Kocak B., Baltaci Z. H., Denizli A., Karademir Yilmaz B., GÜLHAN R., "Effect of methylglyoxal on Parkinson’s disease pathophysiology in the rotenone model", Marmara Medical Journal, cilt.37, sa.2, ss.166-177, 2024
dc.identifier.doi10.5472/marumj.1480086
dc.identifier.endpage177
dc.identifier.issn1019-1941
dc.identifier.issue2
dc.identifier.startpage166
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85196211898&origin=inward
dc.identifier.urihttps://hdl.handle.net/11424/297492
dc.identifier.volume37
dc.language.isoeng
dc.relation.ispartofMarmara Medical Journal
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectMedicine
dc.subjectHealth Sciences
dc.subjectFundamental Medical Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & DAHİLİ
dc.subjectClinical Medicine (MED)
dc.subjectCLINICAL MEDICINE
dc.subjectMEDICINE, GENERAL & INTERNAL
dc.subjectGenel Tıp
dc.subjectGeneral Medicine
dc.subjectLocomotor activity
dc.subjectMethylglyoxal
dc.subjectParkinson’s disease
dc.subjectRotenone
dc.subjectType 2 diabetes mellitus
dc.subjectTyrosine hydroxylase
dc.titleEffect of methylglyoxal on Parkinson’s disease pathophysiology in the rotenone model
dc.typearticle
dspace.entity.typePublication
local.avesis.id266ca7b5-0be9-4cd9-9f7f-dfc6a3be5343
local.indexed.atSCOPUS
relation.isAuthorOfPublication81633a07-e5fb-4760-b3ef-bf0878d87827
relation.isAuthorOfPublicationc44fef14-869d-4c28-a766-5e080b17c687
relation.isAuthorOfPublication.latestForDiscovery81633a07-e5fb-4760-b3ef-bf0878d87827

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
file.pdf
Size:
1.13 MB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs